EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review

Claudia Iannone iD, Luca Marelli, Stefania Costi, Maria Rosa Pellico, Lamberto La Franca, Roberto Caporali, Elisabetta Miserocchi

Children · 23.02.2023 · 10 (3) · 434

DOI: 10.3390/children10030434 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Children, online erschienen am 23.02.2023. Verfasst von Claudia Iannone und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, 20122 Milan, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Juvenile idiopathic arthritis (JIA) associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, affecting 10–15% of patients, especially in oligoarticular JIA where its course may be faint. Therefore, JIA-U is one of the most challenging pediatric uveitis, associated with major ocular morbidity and possibly leading to irreversible structural ocular damage and to vision-threatening complications. Adequate management is crucial for avoiding visual impairment complications. Since the introduction of biologic disease modifying anti-rheumatic drugs (bDMARDS), the visual prognosis of JIA-U has dramatically improved over the decades. Tumor necrosis factor-α (TNF-α) blockers are the most used bDMARDs in treating JIA-U with large evidence of efficacy. However, inadequate response to these agents, either due to intolerance or inefficacy, may be observed, requiring a swap to other classes of immunosuppressive agents, including anti-IL-6, anti-CD20, and, more recently, JAK inhibitors. Tocilizumab is a humanized monoclonal antibody to the interelukin-6 receptor preventing IL-6 from binding to its soluble and membrane-bound receptors. A growing body of literature provides promising results about the efficacy of intravenous and subcutaneous tocilizumab in the treatment of JIA-U. A narrative review of the literature on this topic will improve our knowledge on the potential use of tocilizumab in JIA-U.

Schlagwörter

Stichwörter der Autor:innen

bDMARDsjuvenile idiopathic arthritistocilizumabuveitis

Autor:innen und Institutionen

  • Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, 20122 Milan, Italy.
  • Faculty of Medicine, University of Milan, 20122 Milan, Italy.
  • Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan, 20122 Milan, Italy.
  • Ophthalmology Department, Ospedale San Raffaele, University Vita-Salute, 20132 Milan, Italy.

ORCID-Profile: Claudia Iannone

Zitieren

APA

Iannone, C., Marelli, L., Costi, S., Pellico, M. R., La Franca, L., Caporali, R., & Miserocchi, E. (2023). Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review. Children, 10(3), 434. https://doi.org/10.3390/children10030434

Vancouver

Iannone C, Marelli L, Costi S, Pellico MR, La Franca L, Caporali R, et al. Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review. Children. 2023;10(3):434. doi:10.3390/children10030434

BibTeX
@article{Iannone2023,
  author = {Iannone, Claudia and Marelli, Luca and Costi, Stefania and Pellico, Maria Rosa and La Franca, Lamberto and Caporali, Roberto and Miserocchi, Elisabetta},
  title = {Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review},
  journal = {Children},
  year = {2023},
  volume = {10},
  number = {3},
  pages = {434},
  doi = {10.3390/children10030434}
}
Kostenlos starten →